NO20060808L - Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom - Google Patents

Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom

Info

Publication number
NO20060808L
NO20060808L NO20060808A NO20060808A NO20060808L NO 20060808 L NO20060808 L NO 20060808L NO 20060808 A NO20060808 A NO 20060808A NO 20060808 A NO20060808 A NO 20060808A NO 20060808 L NO20060808 L NO 20060808L
Authority
NO
Norway
Prior art keywords
treatment
joint disease
pak
pak inhibitor
inhibitor
Prior art date
Application number
NO20060808A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Leeuw
Ekkehard Leberer
Eckart Bartnik
Joerg Czech
Sebastian Barradeau
Andreas Klatt
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20060808L publication Critical patent/NO20060808L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
NO20060808A 2003-07-18 2006-02-20 Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom NO20060808L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03016303A EP1498133A1 (fr) 2003-07-18 2003-07-18 Utilisation d'inhibiteur de pak pour le traitement d'une maladie articulaire
PCT/EP2004/007855 WO2005011721A2 (fr) 2003-07-18 2004-07-15 Utilisation d'un inhibiteur de pak pour le traitement d'une maladie des articulations

Publications (1)

Publication Number Publication Date
NO20060808L true NO20060808L (no) 2006-04-12

Family

ID=33462155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060808A NO20060808L (no) 2003-07-18 2006-02-20 Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom

Country Status (14)

Country Link
EP (3) EP1498133A1 (fr)
JP (1) JP4843487B2 (fr)
KR (2) KR101238755B1 (fr)
CN (1) CN1826130B (fr)
AU (1) AU2004260590B2 (fr)
BR (1) BRPI0412760A (fr)
CA (1) CA2532742C (fr)
HK (1) HK1096854A1 (fr)
IL (3) IL173145A (fr)
MX (1) MXPA06000637A (fr)
NO (1) NO20060808L (fr)
RU (1) RU2360696C2 (fr)
WO (1) WO2005011721A2 (fr)
ZA (1) ZA200510377B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US20070264678A1 (en) 2005-10-28 2007-11-15 Invitrogen Corporation Kinase and ubiquination assays
EP1981521A2 (fr) * 2006-01-24 2008-10-22 University Of Virginia Patent Foundation Compositions et methodes visant a inhiber la fonction leucocytaire
KR100835795B1 (ko) * 2006-11-17 2008-06-09 김응국 키나아제 팩2의 활성을 저해하는 펩타이드
WO2010013498A1 (fr) 2008-08-01 2010-02-04 学校法人聖マリアンナ医科大学 Agent thérapeutique ou agent préventif pour l'arthrose
US8513308B2 (en) 2008-08-08 2013-08-20 The Board Of Trustees Of The University Of Illinois PAK1 agonists and methods of use
GB0814570D0 (en) * 2008-08-08 2008-09-17 Diagnostics For The Real World Isolation of nucleic acid
WO2010115841A1 (fr) * 2009-04-01 2010-10-14 Galapagos Nv Procédés et moyens de traitement de l'arthrite
CN102811737A (zh) 2010-01-29 2012-12-05 阿克西斯股份有限公司 骨关节炎治疗及预防药物组合物和上述组合物的制造方法
JP5792636B2 (ja) 2010-01-29 2015-10-14 Ａｘｉｓ株式会社 変形性関節症治療剤を含有する注射剤
JP2012246222A (ja) 2010-01-29 2012-12-13 Axis Inc 変形性関節症治療剤または予防剤を製造するための使用
CA3064469A1 (fr) * 2017-06-02 2018-12-06 Merck Patent Gmbh Immunoglobulines de liaison a mmp13
CN114042053B (zh) * 2021-10-25 2023-07-25 北京理工大学 siRNA输送载体及其制备方法和应用
WO2023097475A1 (fr) * 2021-11-30 2023-06-08 绍兴守仁医疗健康科技有限公司 Procédé de construction d'un vecteur d'expression eucaryote de protéine pak1 humaine, procédé d'expression et procédé de purification
CN114767864B (zh) * 2022-05-10 2023-05-12 天津医科大学总医院 Pak3抑制剂在治疗瑞芬太尼诱发的切口痛觉过敏中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
DK0725788T3 (da) 1993-10-27 1999-08-23 Ribozyme Pharm Inc 2'-amido- og 2'-peptidomodificerede oligonukleotider
US5518911A (en) * 1995-01-06 1996-05-21 Onyx Pharmaceuticals, Inc. Human PAK65
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
GB9602326D0 (en) 1996-02-06 1996-04-03 Cruachem Ltd Compounds
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
EP0889723B1 (fr) 1996-03-25 2002-06-05 LTS LOHMANN Therapie-Systeme AG Systeme therapeutique transdermique a faible epaisseur de la zone d'application et a grande souplesse, et son procede de fabrication
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
WO1998037240A1 (fr) 1997-02-24 1998-08-27 Tm Technologies, Inc. Agents pharmacologiques a base d'oligonucleotides antisens
US6383734B1 (en) * 1998-09-30 2002-05-07 Advanced Research And Technology Institute, Inc. Method to determine inhibition of PAK3 activation of Raf-1
AU3566200A (en) * 1999-04-01 2000-10-23 Astrazeneca Uk Limited Human signal transduction serine/threonine protein kinase

Also Published As

Publication number Publication date
IL173145A (en) 2010-12-30
EP1648486A2 (fr) 2006-04-26
CN1826130B (zh) 2012-08-29
ZA200510377B (en) 2006-10-25
JP4843487B2 (ja) 2011-12-21
CN1826130A (zh) 2006-08-30
WO2005011721A2 (fr) 2005-02-10
IL173145A0 (en) 2006-06-11
KR20060052832A (ko) 2006-05-19
RU2360696C2 (ru) 2009-07-10
IL198727A (en) 2011-03-31
HK1096854A1 (en) 2007-06-15
WO2005011721A3 (fr) 2005-04-21
KR101238755B1 (ko) 2013-03-07
KR101299936B1 (ko) 2013-08-26
IL204861A (en) 2011-09-27
KR20120034250A (ko) 2012-04-10
JP2007537134A (ja) 2007-12-20
EP1498133A1 (fr) 2005-01-19
CA2532742C (fr) 2013-07-09
AU2004260590B2 (en) 2010-06-03
BRPI0412760A (pt) 2006-09-26
AU2004260590A1 (en) 2005-02-10
CA2532742A1 (fr) 2005-02-10
RU2006105013A (ru) 2006-06-27
MXPA06000637A (es) 2006-08-23
EP2275116A1 (fr) 2011-01-19

Similar Documents

Publication Publication Date Title
NO20060808L (no) Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom
ECSP066411A (es) Tienopirazoles
NO20071078L (no) Antivirale forbindelser
NO20070866L (no) Antivirale forbindelser.
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
GT200900147A (es) Derivados de pirimidina y los métodos para su uso
WO2004078682A3 (fr) Composes cycliques et compositions servant d'inhibiteurs de proteines-kinases
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20092274L (no) Ansamycinformuleringer og fremgangsmater for anvendelse derav
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
SI1536827T1 (sl) Uporaba protein-kinaze n beta
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
EA200900959A1 (ru) Ингибиторы мек
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
NO20056046L (no) Oralt dispergerbar flerlags tablett
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
CY1107294T1 (el) Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20084749L (no) Organiske forbindelser og deres anvendelser
NO20051838L (no) Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor.
NO20014986D0 (no) 4,5-diaryl-3(2H)-furanonderivater som cyklooksygenase-2- inhibitorer
MX2022004937A (es) Inhibidores de las cinasas raf.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application